Evidence map›Paper›PMID 39034351›Full record

ArticleScience China. Life sciences2024

Single-cell immune landscape of measurable residual disease in acute myeloid leukemia.

Xiaodong Mo, Weilong Zhang, Guomei Fu, Yingjun Chang, Xiaohui Zhang, Lanping Xu, Yu Wang, Chenhua Yan, Mengzhu Shen, Qiuxia Wei and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Science China. Life sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Advancements in diagnosis and treatments of acute leukemia.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2026
    Article
  3. Review
  4. Review
  5. Observational
  6. CD8Science China. Life sciences · 2026
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xiaodong Mo *Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Beijing, 100044, China.
Weilong Zhang *Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, 100191, China.
Guomei Fu *Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Beijing, 100044, China.
Yingjun ChangPeking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Beijing, 100044, China.
Xiaohui ZhangPeking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Beijing, 100044, China.
Lanping XuPeking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Beijing, 100044, China.
Yu WangPeking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Beijing, 100044, China.
Chenhua YanPeking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Beijing, 100044, China.
Mengzhu ShenPeking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Beijing, 100044, China.
Qiuxia WeiDepartment of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, 100191, China.
Changjian YanDepartment of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, 100191, China.
Xiaojun HuangPeking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Beijing, 100044, China. huangxiaojun@bjmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Measurable residual disease (MRD) is a powerful prognostic factor of relapse in acute myeloid leukemia (AML). We applied the single-cell RNA sequencing to bone marrow (BM) samples from patients with (n=20) and without (n=12) MRD after allogeneic hematopoietic stem cell transplantation. A comprehensive immune landscape with 184,231 cells was created. Compared with CD8

Indexed as

CD8-Positive T-LymphocytesLeukemia, Myeloid, AcuteNeoplasm, ResidualSingle-Cell AnalysisAdultBone MarrowFemaleHematopoietic Stem Cell TransplantationHumansMaleMiddle AgedPrognosisacute myeloid leukemiaallogeneic hematopoietic stem cell transplantationimmune landscapemeasurable residual diseasesingle-cell RNA sequencing

Identifiers

PMID39034351

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.